Radioiodine Therapy for Juvenile Graves’ Disease: A Single Institution Experience in Japan (Poster 317) - oneGRAVESvoice
Global Search
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Abstracts & Posters

Radioiodine Therapy for Juvenile Graves’ Disease: A Single Institution Experience in Japan (Poster 317)

key information

source: Thyroid

year: 2018

authors: T. Mizokami, K. Hamada, T. Maruta, K. Higashi, J. Tajiri

summary/abstract:

131I radioiodine therapy (RIT) has been applied for juvenile Graves’ disease (GD) in the United States for a long time. However, RIT for juvenile GD has been avoided because of the potential risk of tumorigenesis in Japan. There have been few reports regarding RIT for juvenile GD in Japan. Therefore, we reviewed juvenile GD patients treated with RIT in our thyroid specialty clinic.

We reviewed the medical records of 493 GD patients under the age of 19 who had visited our clinic between January 2000 and December 2016. Each RIT was performed as an outpatient treatment, and the maximum 131I dose was 481 MBq per treatment. One hundred and eleven juvenile GD patients (22 males and 89 females: 10 to 18 years old, median 16 years) underwent RIT. 131I administration was performed once in 83 patients, twice in 25 patients, and three times in 3 patients. The total 131I dose was 133-1,143 MBq (median 481 MBq). The duration of follow-up after the initial RIT ranged from 12–201 months (median 80 months).

organization: Tajiri Thyroid Clinic, Japan

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Powered by

© 2022 rareLife solutions Inc.